by Bone Marrow Transplantation
Researchers describe a novel reduced-intensity conditioning protocol that could potentially resolve a common treatment barrier for adults with sickle cell disease (SCD). Children with SCD...
by Blood Advances
The best timeline for SARS-CoV-2 immunization after undergoing cellular therapy is not known, but recent findings indicate that mRNA SARS-CoV-2 vaccination within 4 months does not appear to...
by Blood
An understanding of extended HLA haplotypes can help narrow down the best choice of haploidentical donor for hematopoietic cell transplantation (HCT), according to results from a multivariable...
by Blood
In vitro and in vivo profiling, along with transcriptomic and metabolomic analyses, showcase the potential of non-activated chimeric antigen receptor (CAR) T-cells as an alternative for tumors...
by Blood Advances
Toxicities related to axicabtagene ciloleucel (axi-cel) can be safely and effectively managed, suggest findings from a single-center study.
by Clinical Cancer Research
While evidence suggests that increasing the share of stem cell-like memory T cells (TSCM) in chimeric antigen receptor (CAR) T-cell products might support immunotherapy for solid tumors, a Phase I...